CASP1 and COVID-19: Nonetheless, a significant decrease in plasma levels of key NLRP3 inflammasome markers, specifically NLRP3, caspase-1, and GSDM-D, was observed in COVID-19 patients who received a 10-day diacerein treatment compared to those who received placebo.